Flex is tasked with finding materials to help extend the product’s battery life, as well as boost measurement accuracy and prepare for high volume manufacturing.
Common Sensing’s Gocap device is designed to attach to existing injector pens and track the user’s insulin intake, sending data to mobile phones and web applications.
“Our partnership with Flex allows us to develop our feature-rich, cost-effective commercial Gocap platform,” Kevin Schmid, chief operating officer of Common Sensing, said in prepared remarks. “We will be working with Flex to utilize their expertise in design and manufacturing to bring our vision and product to market.”
“With our experience designing and building connected, intelligent products for numerous industries – including medical and consumer – Flex has the expertise to help Common Sensing design the right product for their customers, and produce it at the scale required for the rapidly growing diabetes care market,” John Carlson, president of health solutions at Flex, added.
The company’s deal with Flex is timed to support a collaboration with Haselmeier that Common Sensing announced in May. The two companies are working to develop a first-of-its-kind disposable, connected injection pen platform.